INVA Q4 2023 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+30.4% YoY

Gross Profit

$73M84.7% margin

Operating Income

$38M43.7% margin

Net Income

$62M71.7% margin

EPS (Diluted)

$0.76

QoQ Revenue Growth

+27.6%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$33M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$569M

Stockholders' Equity

$675M

Cash & Equivalents

$194M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$66M	+30.4%
Gross Profit	$73M	$53M	+37.2%
Operating Income	$38M	$31M	+21.7%
Net Income	$62M	-$68M	+190.1%

Revenue Segments

Royalty

$66M77%

Product

$20M23%